Omid Hamid

No bio available.

Financial relationships

  • Attribution:
    Self
    Type of financial relationship:
    Professional Services
    Ineligible company:
    Vial Health Tech
    Topic:
    Consulting / Advisory Board
    Date added:
    07/01/2024
    Date updated:
    07/01/2024
  • Attribution:
    Self
    Type of financial relationship:
    Professional Services
    Ineligible company:
    Zelluna
    Topic:
    Consulting / Advisory Board
    Date added:
    07/01/2024
    Date updated:
    07/01/2024
  • Attribution:
    Self
    Type of financial relationship:
    Professional Services
    Ineligible company:
    BMS
    Topic:
    Speaker Bureau
    Date added:
    07/01/2024
    Date updated:
    07/01/2024
  • Attribution:
    Self
    Type of financial relationship:
    Professional Services
    Ineligible company:
    Immunocore
    Topic:
    Speaker Bureau
    Date added:
    07/01/2024
    Date updated:
    07/01/2024
  • Attribution:
    Self
    Type of financial relationship:
    Professional Services
    Ineligible company:
    Novartis
    Topic:
    Speaker Bureau
    Date added:
    07/01/2024
    Date updated:
    07/01/2024
  • Attribution:
    Self
    Type of financial relationship:
    Professional Services
    Ineligible company:
    Pfizer
    Topic:
    Speaker Bureau
    Date added:
    07/01/2024
    Date updated:
    07/01/2024
  • Attribution:
    Self
    Type of financial relationship:
    Professional Services
    Ineligible company:
    Regeneron
    Topic:
    Speaker Bureau
    Date added:
    07/01/2024
    Date updated:
    07/01/2024
  • Attribution:
    Self
    Type of financial relationship:
    Stock
    Ineligible company:
    Bactonix
    Date added:
    07/01/2024
    Date updated:
    07/01/2024
  • Attribution:
    Other
    Type of financial relationship:
    Grant Or Contract
    Ineligible company:
    Arcus
    Topic:
    Contracted Research for Institution
    Date added:
    07/01/2024
    Date updated:
    07/01/2024

Pages

Return to 4th Binaytara Precision Oncology Summit: Current Standards and Emerging Therapies